Article
Targeted therapies and immunotherapy in non-small-cell lung cancer
23 Jun 2016
Abstract excerpt
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumours completely...
Topics
Join the communities discussing this publication.